SOURCE: StockCall

StockCall

February 10, 2011 08:41 ET

Opinions on Salix Pharmaceuticals Ltd. and Watson Pharmaceuticals Inc. -- Generic Drug Makers Extending Their Reach Through Global Expansion and Product Acquisitions

JOHANNESBURG, SOUTH AFRICA--(Marketwire - February 10, 2011) - www.stockcall.com/ offers investors comprehensive research on the drugs - generic industry and has completed analytical research on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at www.stockcall.com/ to have free access to these researches. 

Generic drug makers have been performing well recently, and with a number of lucrative patents for brand-name drugs recently expired or set to expire soon, as well as a number emerging markets being realized, the generic drug industry looks healthy. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the drugs - generic industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the drugs - generic industry can have easy and free access to our analyst research and opinions on Salix Pharmaceuticals Ltd. and Watson Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

The opportunity for growth has not been lost on generic drug companies like Salix Pharmaceuticals Ltd. and Watson Pharmaceuticals Inc. which have taken steps to expand their operations through acquisitions and emerging markets. Watson posted strong 2010 financials, with total net revenue jumping up by over 25 percent. The company has said that in 2011 they will increase product launches in key markets such as Canada, France and the U.K. Investors looking for free research on Watson Pharmaceuticals Inc. are welcome to sign up at www.stockcall.com/WPI100211.pdf.

Salix is also increasing their global presence, and has recently announced that they have entered into an agreement with Progenics Pharmaceuticals for the license rights to Progenics' constipation drug RELISTOR. The multimillion dollar deal will give Salix worldwide (excluding Japan) licensing rights. Investors looking for free research on Salix Pharmaceuticals Ltd. are welcome to sign up at www.stockcall.com/SLXP100211.pdf.

Earnings schedules have Watson Pharmaceuticals financial results set to be released on February 15th, whilst Salix Pharmaceuticals will be posting their earnings next month on March 7th. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information